Zobrazeno 1 - 10
of 377
pro vyhledávání: '"Gillian M. Keating"'
Publikováno v:
Drugs. 77:2025-2036
Ticagrelor (Brilique®) is an orally administered P2Y12 inhibitor. A long-term (maintenance) regimen of ticagrelor 60 mg twice daily is indicated in the EU for coadministration with low-dose aspirin 75–150 mg/day for the secondary prevention of ath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4fe9192cc574782ec841a3b4fff604
https://doi.org/10.1007/s40265-017-0844-8
https://doi.org/10.1007/s40265-017-0844-8
Publikováno v:
Drugs & Therapy Perspectives. 33:361-367
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4) that provides an effective, generally well tolerated and convenient treatment option for moderate to severe plaque psoriasis. In phase 3 trials, 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc5c4a6308d83065da489b222d1db6e
https://doi.org/10.1007/s40267-017-0424-8
https://doi.org/10.1007/s40267-017-0424-8
Autor:
Gillian M. Keating
Publikováno v:
Drugs. 77:1009-1016
Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist. The randomized, double-blind, placebo-controlled, mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d06cbb0e104e8e73952b7014b4ea00e
https://doi.org/10.1007/s40265-017-0756-7
https://doi.org/10.1007/s40265-017-0756-7
Publikováno v:
Drugs & Therapy Perspectives. 33:208-213
Vaxelis® (DTaP5-HB-IPV-Hib vaccine) is a fully liquid, ready-to-use, hexavalent vaccine containing diphtheria toxoid, tetanus toxoid, five acellular pertussis antigens, hepatitis B surface antigen, inactivated poliovirus and the Haemophilus influenz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::720fd0451daa88bde6fa1fec19b5b912
https://doi.org/10.1007/s40267-017-0400-3
https://doi.org/10.1007/s40267-017-0400-3
Autor:
Gillian M. Keating
Publikováno v:
Targeted Oncology. 12:243-253
Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd105c81e3bd5720436bf43f57456cbe
https://doi.org/10.1007/s11523-017-0484-7
https://doi.org/10.1007/s11523-017-0484-7
Autor:
Gillian M. Keating
Publikováno v:
Drugs. 77:563-574
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (THC/CBD, Sativex®, nabiximols) is available in numerous countries worldwide for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity in patients who hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5985741ef85b65e61fae078a0c3e5c57
https://doi.org/10.1007/s40265-017-0720-6
https://doi.org/10.1007/s40265-017-0720-6
Publikováno v:
Drugs & Therapy Perspectives. 33:160-166
Pixantrone (Pixuvri®) is an aza-anthracenedione with a novel mode of action. It is conditionally approved in the EU for use as monotherapy in adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL). In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92a7d9a9dbed581d5e3d2ba69d3e1f52
https://doi.org/10.1007/s40267-017-0391-0
https://doi.org/10.1007/s40267-017-0391-0
Autor:
Gillian M. Keating
Publikováno v:
Drugs. 77:459-472
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving diffi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c647aa02f4d5c6ff1209805a1de4f2c3
https://doi.org/10.1007/s40265-017-0709-1
https://doi.org/10.1007/s40265-017-0709-1
Autor:
Gillian M. Keating
Publikováno v:
Drugs & Therapy Perspectives. 33:95-101
Budesonide/formoterol Easyhaler® is an easy-to-use, convenient, effective and well tolerated option for the treatment of patients with asthma or chronic obstructive pulmonary disease (COPD). This device-metered dry powder inhaler (DPI) contains both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75015e389ad1ae539279f5e621cf6b37
https://doi.org/10.1007/s40267-017-0378-x
https://doi.org/10.1007/s40267-017-0378-x
Autor:
Gillian M. Keating
Publikováno v:
Drugs. 77:201-208
Lifitegrast is a novel small molecule integrin antagonist that blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1). Lifitegrast ophthalmic solution 5% (Xiidra™) was recently approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa2176e376c17aeaaaa9be4634a5304
https://doi.org/10.1007/s40265-016-0681-1
https://doi.org/10.1007/s40265-016-0681-1